Drug Profile
IP 001
Alternative Names: GC - Immunophotonics; inCVAX-GC; inCVAX-IP001; inCVAX-N-dihydro-galacto-chitosan; IP-001Latest Information Update: 26 Dec 2022
Price :
$50
*
At a glance
- Originator Immunophotonics
- Developer Immunophotonics; Swiss Group for Clinical Cancer Research
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Antigen presenting cell stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Soft tissue sarcoma; Solid tumours
- No development reported Breast cancer
Most Recent Events
- 15 Dec 2022 Phase-I/II clinical trials in Colorectal cancer (Second-line therapy or greater, Late-stage disease) in Switzerland, France, United Kingdom, Germany (Intratumoural) (ISRCTN16103145)
- 15 Dec 2022 Phase-I/II clinical trials in Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in United Kingdom, France, Germany, Switzerland (Intratumoural) (ISRCTN16103145)
- 15 Dec 2022 Phase-I/II clinical trials in Soft tissue sarcoma (Late-stage disease, Second-line therapy or greater) in United Kingdom, Germany, France, Switzerland (Intratumoural) (ISRCTN16103145)